Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

Prostate Cancer Metastatic Clinical Trial

— CARD  

Official title:

A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02485691
• Other study ID #: LPS14201
• Secondary ID: 2014-004676-29U1
• Status: Completed
• Phase: Phase 4
• Start date: November 9, 2015
• Est. completion date: March 15, 2021

Study information

• Verified date: May 2022
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

To compare the radiographic progression-free survival (rPFS) (using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 for tumor lesions and Prostate Cancer Working Group 2 (PCWG2) criteria for bone scan lesions or death due to any cause) with chemotherapy (cabazitaxel plus prednisone, Arm A) versus Androgen Receptor (AR)-targeted therapy (enzalutamide or abiraterone acetate plus prednisone, Arm B) in mCRPC participants who have been treated with docetaxel and who had disease progression while receiving AR-targeted therapy within 12 months of AR treatment initiation (less than or equal to [<=]12 months, either before or after docetaxel).

Secondary Objective:

• To compare efficacy for:

• Prostate-specific antigen (PSA) response rate and time to PSA progression (TTPP).

• Progression-free survival (PFS).

• Overall survival (OS).

• Tumor response rate and duration of tumor response.

• Pain response and time to pain progression.

• Symptomatic skeletal event (SSE) rate and time to occurrence of any SSE.

• Health status and Health-related Quality of Life (HRQOL).

• To evaluate the correlation of a signature of resistance to AR-targeted agents with clinical outcome via the analysis of circulating tumor cell (CTC) phenotypes as well as expression and localization of proteins including AR isoforms in CTCs.

• To evaluate safety in the 2 treatment arms.

Description:

The duration of the study per participant was approximately 2 years. Each participant was treated until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment, and each participant was followed after completion of study treatment until death, study cut-off date, or withdrawal of participant consent.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 255
• Est. completion date: March 15, 2021
• Est. primary completion date: March 27, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion criteria :

Histologically confirmed prostate adenocarcinoma.

• Metastatic disease.

• Effective castration with serum testosterone levels less than (<)0.5 ng/mL. If the participant has been treated with Luteinizing hormone-releasing hormone agonist (LHRH) agonists or antagonist (i.e., without orchiectomy), then this therapy should be continued.

• Progressive disease defined by at least one of the following:

• Progression in measurable disease (RECIST 1.1 criteria).

• Appearance of 2 or more new bone lesions (PCWG2).

• Rising Prostate Specific Antigen (PSA) (PCWG2).

• Having received prior docetaxel for at least 3 cycles (before or after an AR-targeted therapy). Docetaxel administration in combination with androgen deprivation therapy (ADT) in metastatic hormone-sensitive disease was considered a prior exposure. Docetaxel rechallenge was allowed.

• Having progressive disease (PD) while receiving AR-targeted therapy with abiraterone acetate or enzalutamide within 12 months of AR treatment initiation (<=12 months), even if treatment duration was longer than 12 months. Participants treated with Abiraterone Acetate + ADT in metastatic hormone-sensitive setting were eligible in the study if they have progressed within 12 months with the AR-targeted agent. Participants having PSA progression only (as per PCWG2) within 12 months were eligible.

• A PSA value of at least 2 ng/mL was required at study entry.

• Prior AR-targeted therapy (abiraterone acetate or enzalutamide) must be stopped at least 2 weeks before study treatment.

• Signed informed consent.

Exclusion criteria:

• Prior chemotherapy other than docetaxel for prostate cancer, except estramustine and except adjuvant/neoadjuvant treatment completed >3 years ago.

• Less than 28 days elapsed from prior treatment with chemotherapy, immunotherapy, radiotherapy, or surgery to the time of randomization.

• Adverse events (excluding alopecia and those listed in the specific exclusion criteria) from any prior anticancer therapy of Grade >1 (National Cancer Institute Common Terminology Criteria [NCI CTCAE] v4.0) at the time of randomization.

• Eastern Cooperative Oncology Group performance status (ECOG PS) >2 (ECOG 2 must be related to prostate cancer, not to other comorbidities).

• Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer were allowed, as well as any other cancer for which treatment has been completed >=5 years ago and from which the participant has been disease-free for >=5 years.

• Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.

• Acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment.

• Participants with reproductive potential who do not agree, in conjunction with their partner, to use accepted and effective method of contraception during the study treatment period and up to 6 months after the last administered dose. The definition of "effective method of contraception" described hereafter: oral contraceptives, combined hormonal intravaginal, transdermal, intra uterine device or condoms was based on respective study treatment labelling and country-specific regulatory requirements, and were documented in the Informed Consent Form.

• Known allergies, hypersensitivity or intolerance to prednisone or excipients of abiraterone acetate, enzalutamide, docetaxel, or polysorbate 80.

• Known history of mineralocorticoid excess or deficiency.

• History of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain arteriovenous malformation, brain metastases, or the use of concomitant medications that may lower the seizure threshold.

• Unable to swallow a whole tablet or capsule.

• Inadequate organ and bone marrow function as evidenced by:

• Hemoglobin <10.0 g/dL;

• Absolute neutrophil count <1.5 * 10^9/L;

• Platelet count <100 * 10^9/L;

• Aspartate aminotransferase/serum glutamic oxaloacetic transaminase and/or alanine aminotransferase/serum glutamic pyruvic transaminase >1.5 * the upper limit of normal (ULN);

• Total bilirubin >1.0 * ULN;

• Potassium <3.5 mmol/L;

• Child-Pugh Class C.

• Contraindications to the use of corticosteroid treatment.

• Symptomatic peripheral neuropathy Grade >=2 (NCI CTCAE v4.0).

• Uncontrolled severe illness or medical condition including uncontrolled diabetes mellitus, history of cardiovascular disease (uncontrolled hypertension, arterial thrombotic events in the past 6 months, congestive heart failure, severe or unstable angina pectoris, recent myocardial infarction within the last 6 months, or uncontrolled cardiac arrhythmia).

• Concomitant vaccination with yellow fever vaccine.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Prostate Cancer Metastatic
• Prostatic Neoplasms

Intervention

Drug:
• cabazitaxel XRP6258
Pharmaceutical form: solution Route of administration: intravenous
• enzalutamide
Pharmaceutical form: capsule Route of administration: oral
• abiraterone acetate
Pharmaceutical form: tablet Route of administration: oral
• prednisone
Pharmaceutical form: tablet Route of administration: oral

Locations

Country	Name	City	State
Austria	Investigational Site Number 040002	Linz
Austria	Investigational Site Number 040003	Wien
Austria	Investigational Site Number 040004	Wien
Belgium	Investigational Site Number 056013	Brugge
Belgium	Investigational Site Number 056007	Brussels
Belgium	Investigational Site Number 056003	Bruxelles
Belgium	Investigational Site Number 056006	Charleroi
Belgium	Investigational Site Number 056001	Gent
Belgium	Investigational Site Number 056005	Leuven
Czechia	Investigational Site Number 203005	Brno
Czechia	Investigational Site Number 203001	Olomouc
Czechia	Investigational Site Number 203002	Plzen
Czechia	Investigational Site Number 203003	Praha 4
France	Investigational Site Number 250010	Clermont Ferrand
France	Investigational Site Number 250006	Lyon Cedex 8
France	Investigational Site Number 250004	Marseille
France	Investigational Site Number 250011	Montpellier
France	Investigational Site Number 250007	Paris
France	Investigational Site Number 250013	Paris
France	Investigational Site Number 250002	Paris Cedex 15
France	Investigational Site Number 250014	Plerin
France	Investigational Site Number 250016	Reims
France	Investigational Site Number 250018	Saint-Mandé
France	Investigational Site Number 250009	Strasbourg
France	Investigational Site Number 250005	Suresnes
France	Investigational Site Number 250008	Tours
France	Investigational Site Number 250001	Villejuif
Germany	Investigational Site Number 276028	Aschaffenburg
Germany	Investigational Site Number 276008	Berlin
Germany	Investigational Site Number 276022	Duisburg
Germany	Investigational Site Number 276023	Essen
Germany	Investigational Site Number 276002	Frankfurt Am Main
Germany	Investigational Site Number 276007	Göttingen
Germany	Investigational Site Number 276026	Jena
Germany	Investigational Site Number 276025	Lübeck
Germany	Investigational Site Number 276004	Magdeburg
Germany	Investigational Site Number 276018	Mannheim
Germany	Investigational Site Number 276006	Münster
Germany	Investigational Site Number 276003	Nürtingen
Germany	Investigational Site Number 276010	Rostock
Germany	Investigational Site Number 276011	Tübingen
Greece	Investigational Site Number 300001	Athens
Greece	Investigational Site Number 300005	Marousi, Athens
Greece	Investigational Site Number 300004	Thessaloniki
Iceland	Investigational Site Number 352001	Reykjavik
Ireland	Investigational Site Number 372001	Dublin 24
Ireland	Investigational Site Number 372003	Dublin 7
Italy	Investigational Site Number 380004	Brescia
Italy	Investigational Site Number 380005	Candiolo
Italy	Investigational Site Number 380009	Meldola
Italy	Investigational Site Number 380006	Napoli
Italy	Investigational Site Number 380002	Pisa
Italy	Investigational Site Number 380001	Roma
Italy	Investigational Site Number 380008	Verona
Netherlands	Investigational Site Number 528002	Breda
Netherlands	Investigational Site Number 528003	Nijmegen
Netherlands	Investigational Site Number 528005	Rotterdam
Netherlands	Investigational Site Number 528004	Sittard-Geleen
Norway	Investigational Site Number 578001	Grålum
Norway	Investigational Site Number 578002	Trondheim
Spain	Investigational Site Number 724001	Barcelona
Spain	Investigational Site Number 724002	Madrid
Spain	Investigational Site Number 724004	Madrid
Spain	Investigational Site Number 724003	Sevilla
United Kingdom	Investigational Site Number 826001	Sutton

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

Austria,  Belgium,  Czechia,  France,  Germany,  Greece,  Iceland,  Ireland,  Italy,  Netherlands,  Norway,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radiographic Progression-Free Survival (rPFS)	Radiographic progression-free survival: time (in months) from randomization to occurrence of any one of following: radiological tumor progressions using response evaluation criteria in solid tumors (RECIST 1.1), progression of bone lesions using Prostate Cancer Working Group 2 (PCWG2) criteria or occurrence of death due to any cause. Progression as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Progression of bone lesions (PCWG2 criteria): first bone scan with >= 2 new lesions compared to Baseline observed less than (<) 12 weeks from randomization and confirmed by a second bone scan performed >=6 weeks; first bone scan with >=2 new lesions compared to Baseline observed >=12 weeks from randomization. In accordance with protocol, data cut-off date for final analysis of this endpoint was the date when 196 rPFS events had occurred. Analysis done by Kaplan-Meier method.	From randomization until tumor progression or bone lesion progression, death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Secondary	Overall Survival (OS)	Overall survival was defined as the time interval (in months) from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date whichever comes first. Analysis was performed by Kaplan-Meier method.	From randomization to death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Secondary	Progression Free Survival (PFS)	PFS:time duration (in months) from date of randomization to date of first occurrence of any of following events: radiological tumor progression (RECIST 1.1); progression of bone lesions (PCWG2); symptomatic progression (developing urinary or bowel symptoms; need to change anti-cancer therapy), pain progression or death due to any cause. Tumor Progression(RECIST 1.1): at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Progression of bone lesion (PCWG2 criteria): first bone scan with >=2 new lesions compared to Baseline and confirmed by second bone scan performed >=6 weeks later; pain progression: increase by >=30% from Baseline in pain intensity score (calculated using scale ranged from 0=no pain to 5=extreme pain) or increase in analgesic usage score >=30% (calculated from analgesic use data, non-narcotic medications assigned value of 1 point and narcotic medications assigned 4 points). Analyzed by Kaplan-Meier method.	From randomization until tumor progression or bone lesion progression, pain progression, death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Secondary	Percentage of Participants With Prostate Specific Antigen (PSA) Response	PSA response was defined as >= 50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later.	Baseline up to PSA response, death due to any cause or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Secondary	Percentage of Participants With Overall Objective Tumor Response	Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.	From randomization until disease progression, death due to any cause or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Secondary	Time to PSA Progression (TTPP)	TTPP was defined as the time duration (in months) between the date of randomization and the date of first documented PSA progression. PSA progression (as per PCWG 2) was defined as: 1) If decline from Baseline value: an increase of >=25% (at least 2 ng/mL) over the nadir value, confirmed by a second PSA value at least 3 weeks apart; 2) If no decline from Baseline value: an increase of >=25% (at least 2 ng/mL) over the baseline value after 12 weeks of treatment, confirmed by a second PSA value at least 3 weeks apart. Analysis performed by Kaplan-Meier method.	From time from randomization until PSA progression, death due to any cause or data cut-off whichever comes first (maximum duration: up to 141 weeks)
Secondary	Duration of Tumor Response	Duration of tumor response was defined as the time (in months) from date of first response (CR or PR) until date of first documentation of tumor progression or death, whichever occurs first. As per RECIST 1.1 CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progression was defined as at least a 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method.	From the date of the first response to the date of first documented tumor progression, or death due to any cause or data cut-off date whichever comes first (maximum duration: up to 141 weeks)
Secondary	Percentage of Participants Achieving Pain Response Assessed Using Brief Pain Inventory-Short Form (BPI-SF) Pain Intensity Score	Pain response as per BPI-SF was defined as a decrease of at least 30% from Baseline in the average of BPI-SF pain intensity score observed at 2 consecutive evaluations >=3 weeks apart without increase in analgesic usage score (calculated from analgesic use data, with non-narcotic medications assigned value of 1 point and narcotic medications assigned 4 points). The BPI-SF is a self-administered questionnaire developed to assess the severity of pain on a 0-10 categorical scale where 0=no pain, 10=pain as bad as you can imagine. Higher scores indicated worst outcomes. Percentage of Participants Achieving Pain Response assessed using BPI-SF Pain Intensity Score were reported.	Baseline until pain progression, first further anticancer therapy, or data cut-off whichever comes first (maximum duration: up to 141 weeks)
Secondary	Time to Pain Progression	Time to pain progression was defined as the time duration (in months) between the date of randomization and the date of first documented pain progression. Pain progression, in participants with no pain or stable pain at Baseline was defined as increase of >=30% from baseline in the BPI-SF pain intensity score observed at 2 consecutive evaluations >=3 weeks apart without decrease in analgesic usage score or increase in analgesic usage score (calculated from analgesic use data, with non-narcotic medications assigned value of 1 point and narcotic medications assigned 4 points) >=30%. The BPI-SF is a self-administered questionnaire developed to assess the severity of pain on a 0-10 categorical scale where 0=no pain, 10=pain as bad as you can imagine. Higher scores indicated worst outcomes. Analysis was performed by Kaplan-Meier method.	Baseline until pain progression or data cut-off whichever comes first (maximum duration: up to 141 weeks)
Secondary	Number of Symptomatic Skeletal Events (SSE)	SSE was defined as occurrence of a new symptomatic pathological fracture, use of external beam radiation to relieve bone pain, occurrence of spinal cord compression or tumor- related orthopedic surgical intervention.	Baseline until occurrence of first SSE or data cut-off, whichever comes first (maximum duration: up to 141 weeks)
Secondary	Time to Symptomatic Skeletal Event	Time to SSE was defined as the time duration (in months) between the date of randomization and the date of occurrence of the first SSE. Analysis was performed by Kaplan-Meier method.	From date of randomization until first SSE, or data cut-off whichever comes first (maximum duration: up to 141 weeks)
Secondary	Health-Related Quality of Life (HRQOL): Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score at Cycle 2, 3, 4, 5, 6, 7, 8 and End of Treatment	Health-related quality of life (HRQOL) evaluation was performed using the FACT-P questionnaire (Version 4). FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms. Baseline corresponded to last evaluable assessment before treatment administration.	Baseline, Day 1 of each Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8 and at End of Treatment (any time up to 141 weeks)
Secondary	Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Utility Single Index and Visual Analogue Scale (VAS) Scores at Cycle 2, 3, 4, 5, 6, 7, 8 and End of Treatment	EQ-5D was a standardized HRQOL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS scale ranging from 0-100, where 0=worst imaginable health state and 100=best imaginable health state, where higher states indicated better outcomes. Baseline corresponded to last evaluable assessment before treatment administration.	Baseline, Day 1 of each Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8 and at End of Treatment (any time up to: 141 weeks)
Secondary	Radiographic Progression-Free Survival (rPFS) in Participants With Presence and Absence of Biomarker	Circulating tumor cell (CTC) counts were considered as biomarker in a liquid biopsy. rPFS in participants with presence and absence of subtypes of CTC biomarker i.e. chromosomal instability (CIN) and neuroendocrine (NE) was reported in this outcome measure. rPFS was defined as: time (in months) from randomization to the first occurrence of any one of following: radiological tumor progressions (RECIST1.1), progression of bone lesions (PCWG2 criteria) or death due to any cause. Progression (RECIST1.1): at least a 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Progression of bone lesions (PCWG2 criteria): first bone scan with >= 2 new lesions compared to Baseline observed <12 weeks from randomization and confirmed by a second bone scan performed >=6 weeks later; first bone scan with >=2 new lesions compared to Baseline observed >=12 weeks from randomization and new lesions were verified on next bone scan >= 6 weeks later.	From randomization until tumor progression or bone lesion progression, death due to any cause, or data cut-off date whichever comes first (maximum duration: up to 141 weeks)